Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer

References

• Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998;90:1138–1145.
   PubMedGoogle Scholar
• Waddell N, Arnold J, Cocciardi S, et al. Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res Treat. 2010;123:661–677.
   PubMed Web of Science ®Google Scholar
• Massink MP, Kooi IE, van Mil SE, et al. Proper genomic profiling of (BRCA1-mutated) basal-like breast carcinomas requires prior removal of tumor infiltrating lymphocytes. Mol Oncol. 2015;9:877–888.
   PubMed Web of Science ®Google Scholar
• Mavaddat N, Barrowdale D, Andrulis IL, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomark Prevent. 2012;21:134–147.
   PubMed Web of Science ®Google Scholar
• Armes JE, Egan AJ, Southey MC, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer. 1998;83:2335–2345.
   PubMed Web of Science ®Google Scholar
• Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer. 1996;77:697–709.
   PubMed Web of Science ®Google Scholar
• Marcus JN, Watson P, Page DL, et al. BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat. 1997;44:275–277.
   PubMed Web of Science ®Google Scholar
• Agnarsson BA, Jonasson JG, Bjornsdottir IB, et al. Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat. 1998;47:121–127.
   PubMed Web of Science ®Google Scholar
• Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. JCO. 2015;33:983–991.
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet (London, England). 2014;384:164–172.
   PubMed Web of Science ®Google Scholar
• Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. JCO. 2013;1;31:860–867.
   PubMed Web of Science ®Google Scholar
• Dieci MV, Mathieu MC, Guarneri V, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol. 2015;26:1698–1704.
   PubMed Web of Science ®Google Scholar
• Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40–50.
   PubMed Web of Science ®Google Scholar
• Mittal D, Gubin MM, Schreiber RD, et al. New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16–25.
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (New York, NY). 2011;331:1565–1570.
   Google Scholar
• Efremova M, Finotello F, Rieder D, et al. Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy. Front Immunol. 2017;8:1679.
   PubMed Web of Science ®Google Scholar
• Strickland KC, Howitt BE, Shukla SA, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7:13587–13598.
   PubMed Web of Science ®Google Scholar
• Stovgaard ES, Nielsen D, Hogdall E, et al. Triple negative breast cancer – prognostic role of immune-related factors: a systematic review. Acta Oncol. 2018;57:74–82.
   PubMed Web of Science ®Google Scholar
• Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol. 2015;26:259–271.
   PubMed Web of Science ®Google Scholar
• Christiansen P, Ejlertsen B, Jensen MB, et al. Danish breast cancer cooperative group. Clin Epidemiol. 2016;8:445–449.
   PubMed Web of Science ®Google Scholar
• Soenderstrup IMH, Laenkholm AV, Jensen MB, et al. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG. Acta Oncol. 2018;57:95–101.
   PubMed Web of Science ®Google Scholar
• DBCG [Internewt]. Clinical guidelines. 2017. Available from: http://dbcg.dk/, accessed March 20, 2018.
   Google Scholar
• Schmidt M, Schmidt SA, Sandegaard JL, et al. The Danish national patient registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490.
   PubMed Web of Science ®Google Scholar
• Bjerregaard B, Larsen OB. The Danish pathology register. Scand J Public Health. 2011;39:72–74.
   PubMed Web of Science ®Google Scholar
• Gjerstorff ML. The Danish cancer registry. Scand J Public Health. 2011;39:42–45.
   PubMed Web of Science ®Google Scholar
• Pedersen IS, Schmidt AY, Bertelsen B, et al. A Danish national effort of BRCA1/2 variant classification. Acta Oncol. 2017;23:1–3.
   Google Scholar
• Thomassen M, Hansen TV, Borg A, et al. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer. Acta Oncol. 2008;47:772–777.
   PubMed Web of Science ®Google Scholar
• Lakhani SREI, Schnitt SO, et al. WHO classification of tumours of the breast. 4th ed. Vol. 4. France: WHO/IARC; 2012.
   Google Scholar
• Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957;11:359–377.
   PubMed Web of Science ®Google Scholar
• Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. JCO. 2010;28:2784–2795.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. JCO. 2013;31:3997–4013.
   PubMed Web of Science ®Google Scholar
• Lee AJ, Cunningham AP, Kuchenbaecker KB, et al. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer. 2014;110:535–545.
   PubMed Web of Science ®Google Scholar
• Tramm T, Di Caterino T, Jylling AB, et al. Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists. Acta Oncol. 2018;57:90–94.
   PubMed Web of Science ®Google Scholar
• Nolan E, Savas P, Policheni AN, et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci Trans Med 2017;9:pii: eaal4922.
   Web of Science ®Google Scholar